Publications

 Publications dont lesquelles l'un de nos scientifiques est impliqué :

  1. Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus. Dubourg, J., Perrimond-Dauchy, S., Felices, M., Bolze, S., Voiriot, P., & Fouqueray, P. (2020). European Journal of Clinical Pharmacology, 76(10), 1393-1400. doi:10.1007/s00228-020-02929-6
  2. Randomized study of the effect of gadopiclenol, a new gadolinium‐based contrast agent, on the QTc interval in healthy subjects. Funck‐Brentano, C., Felices, M., Fur, N. L., Dubourdieu, C., Desché, P., Vanhoutte, F., & Voiriot, P. (2020). British Journal of Clinical Pharmacology, 86(11), 2174-2181. doi:10.1111/bcp.14309
    https://pubmed.ncbi.nlm.nih.gov/32302009/
  3. Bioequivalence study of two Ibuprofen formulations administered intravenously in healthy male volunteers Chassard D, Geneteau A, Gualano V, Brault M. Clin. Drug. Invest. 24(12): 739-747, 2004
    http://www.ncbi.nlm.nih.gov/pubmed/17523737
  4. Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency Chatelut E, Rostaing L, Gualano V, Vissac T, De Forni M, Ton-That H, Suc JM, Houin G, Canal P. Nephron. 66(2):157-61, 1994
    http://www.ncbi.nlm.nih.gov/pubmed/8139735
  5. Continuous double administration of 5 fluorouracil (intravenous and intraperitoneal) modulated by folinic acid: phase I clinical study and pharmacokinetics in patients with intra-abdominal developing cancers de Forni M, Gualano V, Canal P, Martel P, Izar-Soum F, Chevreau C, Soulie P, Roche H, Bugat R. Bull Cancer 80(5):408-17, 1993 (French)
    http://www.ncbi.nlm.nih.gov/pubmed/8173194
  6. Comparative bioavailability study of two omeprazole formulations after single and repeated administrations Duvauchelle T., Millérioux L., Gualano V. Evène E., Alcaïde A., Clin. Drug Investigation, 16, 141 –149, 1998
    http://www.ncbi.nlm.nih.gov/pubmed/18370532
  7. Population pharmacokinetics of ibuprofen enantiomers in very premature neonates Grégoire N, Gualano V, Geneteau A, Millerioux L, Brault M, Mignot A, Roze J.C. J Clin Pharmacol. 44: 1114-24, 2004
    http://www.ncbi.nlm.nih.gov/pubmed/15342612
  8. Safety and pharmacokinetics of paracetamol following intravenous administration of 5 g during the first 24 h with a 2-g starting dose Gregoire N, Hovsepian L, Gualano V, Evène E, Dufour G, Gendron A. Clin. Pharm; Ther., 81(3):401-5, 2007
    http://www.ncbi.nlm.nih.gov/pubmed/17339870
  9. Comparative bioavailability of two oral nimodipine formulations after administration to 24 healthy volunteers Gualano V, Ntssikoussalabongui B, Mignot A, Duvauchelle T, Felices M, Guillaume M, Orlandini B, Holguin J, Alcaïde A.. Clin. Drug Investig. 17; 6: 475-82, 1999
    http://www.ingentaconnect.com/content/adis/cdi/1999/00000017/00000006/art00008
  10. Multiple-dose pharmacokinetics and excretion balance of gatifloxacin, a new fluoroquinolone antibiotic, following oral administration to healthy Caucasian volunteers Mignot A, Guillaume M, Brault M, Gualano V, Millerioux L, Gohler K, Stahlberg HJ. Chemotherapy. 48(3):116-21, 2002
    http://www.ncbi.nlm.nih.gov/pubmed/12138326

  11. High-performance liquid chromatographic determination of baclofen in human plasma Millerioux L, Brault M, Gualano V, Mignot A. J Chromatogr A. 5;729(1-2):309-14, 1996
    http://www.ncbi.nlm.nih.gov/pubmed/9004955

  12. Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study Montastruc JL, Rascol O, Senard JM, Gualano V, Bagheri H, Houin G, Lees A, Rascol A. Clin. Neuropharmacol. , 14(5):432-7, 1991
    http://www.ncbi.nlm.nih.gov/pubmed/1742752

  13. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion Muller C, Chatelut E, Gualano V, De Forni M, Huguet F, Attal M, Canal P, Laurent G. Cancer Chemother Pharmacol.; 32(5): 379-84, 1993
    http://www.ncbi.nlm.nih.gov/pubmed/8339389

  14. Pharmacokinetics and tolerability of prulifloxacin after single oral administration Picollo R, Brion N, Gualano V, Millerioux L, Marchetti M, Rosignoli MT, Dionisio P. Arzneimittelforschung; 53(3):201-5, 2003
    http://www.ncbi.nlm.nih.gov/pubmed/12705176

  15. Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men Raynaud JP, Aumonier C, Gualano V, Betea D, Beckers A. J Steroid Biochem Mol Biol, 109(1-2):177-84, 2008
    http://www.ncbi.nlm.nih.gov/pubmed/18325758

  16. Plasma levels of glyceryl trinitrate and dinitrates during application of three strengths of a new glyceryl trinitrate transdermal patch Santoro A, Rovati LC, Follet M, Setnikar I, Caplain H, Gualano V. Arzneimittelforschung;50(9):786-94, 2000
    http://www.ncbi.nlm.nih.gov/pubmed/11050694

  17. Bioavailability and pharmacokinetic profile of glyceryl trinitrate and of glyceryl dinitrates during application of a new glyceryl trinitrate transdermal patch Santoro A, Rovati LC, Setnikar I, Caplain H, Gualano V. Arzneimittelforschung, 50(9): 779-85, 2000
    http://www.ncbi.nlm.nih.gov/pubmed/11050693

  18. Estradiol and estrone plasma levels during application of three strengths of a 7-day estradiol transdermal patch Setnikar I, Rovati LC, Santoro A, Guillaume M, Mignot A, Renoux A, Gualano V. Arzneimittelforschung; 49(8): 708-15, 1999
    http://www.ncbi.nlm.nih.gov/pubmed/10483519

  19. Pharmacokinetics of estradiol and of estrone during application of three strengths of an estradiol transdermal patch with active matrix Setnikar I, Rovati LC, Thebault JJ, Guillaume M, Mignot A, Renoux A, Gualano V. Arzneimittelforschung, 47(7):859-65, 1997
    http://www.ncbi.nlm.nih.gov/pubmed/9272245

  20. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors. Tranchand B, Catimel G, Lucas C, Sarkany M, Bastian G, Evene E, Guastalla JP, Négrier S, Rebattu P, Dumortier A, Foy M, Grossin F, Mazier B, Froudarakis M, Barbet N, Clavel M, Ardiet C. Cancer Chemother Pharmacol. 1998
    http://www.ncbi.nlm.nih.gov/pubmed/9488597

  21. Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149. Dirix L, Catimel G, Koier I, Provè A, Schrijvers D, Joossens E, De Bruijn E, Ardiet C, Evene E, Dumortier A, et al. Anticancer Drugs. 1995
    http://www.ncbi.nlm.nih.gov/pubmed/7756684

  22. A single-center, open-label, cross-over study of pharmacokinetics comparing topical zinc/clindamycin gel (Zindaclin) and topical clindamycin lotion (Dalacin® T) in subjects with mild to moderate acne Chassard D, Kanis R, Namour F, Evène E, Ntssikoussalabongui B, Schmitz V., J Dermatolog Treat, 17(3): 154-157, 2006
    http://www.ncbi.nlm.nih.gov/pubmed/16854755

  23. Bayesian estimation of pharmacokinetic parameters of etoposide Evène E., Tranchand B., Chatelut E., Canal P., Ardiet C.. Bulletin du Cancer, 84, 699 – 703, 1997(French)
    http://www.ncbi.nlm.nih.gov/pubmed/9339195

  24. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.Descamps D, Lambert-Niclot S, Marcelin AG, Peytavin G, Roquebert B, Katlama C, Yeni P, Felices M, Calvez V, Brun-Vézinet F. J Antimicrob Chemother, 63(3):585-92, 2009
    http://www.ncbi.nlm.nih.gov/pubmed/19147519

  25. Bioequivalence study of two formulations (sachet and tablet) of cefixime after single oral doses of 200 mg in healthy male volunteers. Evène E., Brault M., Manche M., Sibille M., Montay G., Vital Durand D., Clin. Drug Investigation, 21, 287 – 94, 2001
    http://www.ingentaconnect.com/content/adis/cdi/2001/00000021/00000004/art00007

  26. Pharmacokinetics of repaglinide in healthy Caucasian and Japanese Subjects Thomsen M.S., Chassard D., Evène E., K.K. Nielsen, M. Jørgensen., J Clin Pharmacol, 43, 23-28, 2003
    http://www.ncbi.nlm.nih.gov/pubmed/12520624

  27. Phase I pharmacokinetic study of high dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas Tranchand B., Lucas C., Biron P., Giroux B., Gordon B., Richards R., Solere P., Roux N., Evène E., Mornex F., Clavel M., Ardiet C. Cancer Chemother. Pharmacol., 32, 46 – 52, 1993
    http://www.ncbi.nlm.nih.gov/pubmed/8462123

  28. Statistical investigation of the full concentration range of fasted and fed simulated intestinal fluid on the equilibrium solubility of oral drugs Jeremy Perrier, Zhou Zhou, Claire Dunn, Ibrahim Khadra, Clive G Wilson, Gavin Halbert European Journal of Pharmaceutical Sciences. Elsevier, 111(June 2017), pp. 247–256
    https://www.ncbi.nlm.nih.gov/pubmed/28987539

  29. Dual level statistical investigation of equilibrium solubility in simulated fasted and fed intestinal fluid. Bayan E Ainousah, Jeremy Perrier, Zhou Zhou, Claire Dunn, Ibrahim Khadra, Clive G Wilson, Gavin Halbert Mol. Pharmaceutics, 2017, 14 (12), pp 4170-4180
    https://www.ncbi.nlm.nih.gov/pubmed/29072917

  30. The topography of simulated intestinal equilibrium solubility Claire Dunn, Jeremy Perrier, Zhou Zhou, Ibrahim Khadra, Clive G Wilson, Gavin Halbert Mol. Pharm. 2019 May 6;16(5):1890-1905
    https://www.ncbi.nlm.nih.gov/pubmed/30848917

  31. Effects of Dihydroartemisinin-Piperaquine Phosphate and Artemether-Lumefantrine on QTc Interval Prolongation Christian Funck-Brentano, Antonella Bacchieri, Giovanni Valentini, Silvia Pace, Silva Tommasini, Pascal Voiriot, David Ubben, Stephan Duparc, Eric Evene, Mathieu Felices & Marco Corsi Scientific Reports 9(1):883 · December 2019
    https://www.nature.com/articles/s41598-018-37112-6

  32. Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method Christian Funck-Brentano, Nouhoum Ouologuem, Stephan Duparc, Mathieu Felices, Sodiomon B. Sirima, Issaka Sagara, Issiaka Soulama, Jean-Bosco Ouedraogo, Abdoul H. Beavogui, Isabelle Borghini-Fuhrer, Yasmin Khan, Abdoulaye A. Djimdé & Pascal Voiriot Sci Rep. 2019 Jan 29;9(1):883
    https://www.ncbi.nlm.nih.gov/pubmed/30696921

  33. Can an early phase clinical pharmacology study replace a thorough QT study? Experience with a novel H3-receptor antagonist/inverse agonist Rashmi R Shah, Pierre Maison-Blanche, Philippe Robert, Emmanuel Denis, Thierry Duvauchelle Eur J Clin Pharmacol. 2016 May;72(5):533-43
    https://www.ncbi.nlm.nih.gov/pubmed/26879827

  34. A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years Mario Scala, Meriam Koob, Sophie de Buttet, Philippe Bourrinet, Mathieu Felices and Elzbieta Jurkiewicz Invest Radiol. 2018 Feb;53(2):70-79
    https://www.ncbi.nlm.nih.gov/pubmed/28906338

  35. Determination of an Optimal Dosing Regimen for Fexinidazole, a Novel Oral Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Studies Antoine Tarral, Séverine Blesson, Olaf Valverde Mordt, Els Torreele, Daniela Sassella, Michael A. Bray, Lionel Hovsepian, Eric Evène, Virginie Gualano, Mathieu Felices, and Nathalie Strub-Wourgaft Clin Pharmacokinet. 2014; 53(6): 565–580.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037587/

BioQuébec
Montreal International
GMP - Groupe de Métabolisme et Pharmacocinétique
EUFEMED
AFSSI
AFPT